Compare Stocks: ARDX, LQDA, MOR, and HCM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$3.08 -3.8%	$3.52	$3.02 ▼ $8.40	$797.40M	0.68	4.29 million shs	4.81 million shs
HCM HUTCHMED	$14.36 +0.6%	$13.57	$9.77 ▼ $16.33	$2.49B	0.18	52,029 shs	23,386 shs
LQDA Liquidia	$42.65 +7.5%	$55.83	$22.05 ▼ $93.61	$3.55B	0.61	7.25 million shs	3.80 million shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	-3.75%	-0.32%	-11.49%	-38.77%	-40.19%
HCM HUTCHMED	+0.56%	+2.21%	-0.07%	+30.43%	-4.96%
LQDA Liquidia	+7.46%	+24.16%	-36.81%	-50.53%	+90.91%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$3.08 -3.8%	$3.52	$3.02 ▼ $8.40	$797.40M	0.68	4.29 million shs	4.81 million shs
HCM HUTCHMED	$14.36 +0.6%	$13.57	$9.77 ▼ $16.33	$2.49B	0.18	52,029 shs	23,386 shs
LQDA Liquidia	$42.65 +7.5%	$55.83	$22.05 ▼ $93.61	$3.55B	0.61	7.25 million shs	3.80 million shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	-3.75%	-0.32%	-11.49%	-38.77%	-40.19%
HCM HUTCHMED	+0.56%	+2.21%	-0.07%	+30.43%	-4.96%
LQDA Liquidia	+7.46%	+24.16%	-36.81%	-50.53%	+90.91%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	2.83	Moderate Buy	$13.90	351.30% Upside
HCM HUTCHMED	2.67	Moderate Buy	$14.87	3.53% Upside
LQDA Liquidia	2.42	Hold	$72.85	70.80% Upside
MOR MorphoSys	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ARDX, LQDA, MOR, and HCM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/20/2026	HCM HUTCHMED	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D) ➝ Sell (D+)
10/16/2026	ARDX Ardelyx	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
10/15/2026	LQDA Liquidia	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$65.00
10/15/2026	LQDA Liquidia	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$58.00 ➝ $65.00
10/14/2026	LQDA Liquidia	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Equal Weight	$30.00 ➝ $33.00
10/14/2026	LQDA Liquidia	Lifesci Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Outperform	$59.00
10/14/2026	LQDA Liquidia	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Buy	$70.00
10/14/2026	LQDA Liquidia	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$72.00 ➝ $58.00
10/8/2026	LQDA Liquidia	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
10/2/2026	LQDA Liquidia	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$58.00
10/2/2026	LQDA Liquidia	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight ➝ Equal Weight	$108.00 ➝ $30.00

(Data available from 10/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$450.89M	1.70	N/A	N/A	$0.69 per share	4.46
HCM HUTCHMED	$549.12M	4.56	$2.71 per share	5.30	$7.17 per share	2.00
LQDA Liquidia	$450.91M	8.47	N/A	N/A	$0.51 per share	83.63
MOR MorphoSys	$238.28M	11.99	N/A	N/A	$0.35 per share	54.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$61.60M	-$0.22	N/A	12.83	N/A	-12.35%	-36.00%	-10.77%	11/3/2026 (Estimated)
HCM HUTCHMED	$456.91M	N/A	N/A	65.27	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia	-$68.92M	$1.37	31.13	20.02	0.35	30.74%	149.65%	36.30%	11/2/2026 (Estimated)
MOR MorphoSys	-$205.35M	-$3.48	N/A	N/A	N/A	-226.79%	-694.31%	-22.55%	N/A

Latest ARDX, LQDA, MOR, and HCM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	ARDX Ardelyx	-$0.0148	N/A	N/A	N/A	$128.66 million	N/A
11/2/2026	Q3 2026	LQDA Liquidia	$0.9220	N/A	N/A	N/A	$214.18 million	N/A
8/12/2026	Q2 2026	LQDA Liquidia	$0.7580	$0.74	-$0.0180	$0.74	$168.48 million	$171.68 million
8/6/2026	Q2 2026	ARDX Ardelyx	-$0.05	-$0.07	-$0.02	-$0.07	$121.04 million	$120.88 million
7/30/2026	H1 2026	HCM HUTCHMED	$0.1450	$0.05	-$0.0950	$0.05	$304.16 million	$139.14 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia	N/A	N/A	N/A	N/A	N/A
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	1.69	3.34	3.15
HCM HUTCHMED	0.06	5.64	5.50
LQDA Liquidia	0.63	2.31	2.12
MOR MorphoSys	4.98	1.38	1.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
HCM HUTCHMED	8.82%
LQDA Liquidia	64.54%
MOR MorphoSys	18.38%

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	5.30%
HCM HUTCHMED	3.60%
LQDA Liquidia	25.60%
MOR MorphoSys	0.05%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	489	249.19 million	235.98 million	Optionable
HCM HUTCHMED	1,796	174.47 million	168.19 million	Optionable
LQDA Liquidia	216	89.51 million	66.60 million	Optionable
MOR MorphoSys	730	150.62 million	150.55 million	No Data

ARDX, LQDA, MOR, and HCM Headlines

Recent News About These Companies

Morphosys AG : MOR

May 31, 2026 | 247wallst.com

Patent case unblocks antibody businesses

May 25, 2026 | nature.comN

Novartis Drug Ianalumab Succeeds in Second Indication

December 11, 2025 | thesiliconreview.comT

Novartis notches another win for drug acquired in MorphoSys deal

December 9, 2025 | finance.yahoo.com

Novartis drug reduces Sjögren's activity, patient burden in late-stage trials despite notable placebo effect

October 29, 2025 | fiercebiotech.comF

Novartis' Avidity Deal: Growth Accretive, Multiple Gated By Execution

October 27, 2025 | seekingalpha.com

Myelofibrosis Market Overview: Epidemiology, Therapies, and Key Players include AbbVie, Morphosys, Geron, Bristol Myers Squibb, Kartos Therapeutics, Karyopharm Therapeutics, NS ...

October 7, 2025 | theglobeandmail.com

MorphoSys takeover delivers phase 3 win for Novartis

August 11, 2025 | pharmaphorum.comP

Novartis drug acquired in Morphosys deal succeeds against tough-to-treat autoimmune disease

August 11, 2025 | biopharmadive.comB

Maxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development Officer

June 17, 2025 | finance.yahoo.com

Essential Thrombocythemia Market Set for Significant Growth Across 7MM | DelveInsight

March 21, 2025 | theglobeandmail.com

Royalty Pharma targets $3B share buyback and projects 4-9% growth in 2025 portfolio receipts

February 12, 2025 | seekingalpha.com

VIDEO: Triplet therapy improved PFS in relapsed, refractory follicular lymphoma

January 15, 2025 | healio.comH

Novartis closing Morphosys facilities, laying off 330 workers

January 8, 2025 | bioworld.comB

Swiss pharma giant Novartis to close biotech firm Morphosys

December 20, 2024 | swissinfo.chS

Novartis to shut MorphSys sites amid pelabresib delay

December 20, 2024 | thepharmaletter.comT

Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs

December 19, 2024 | biospace.comB

Novartis sheds MorphoSys staff, sites after pelabresib delay

December 19, 2024 | pharmaphorum.comP

Novartis shutters MorphoSys sites, lays off staff

December 19, 2024 | finance.yahoo.com

Some 330 jobs hit as Novartis closes Morphosys, WiWo reports

December 19, 2024 | reuters.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ARDX, LQDA, MOR, and HCM Company Descriptions

Ardelyx NASDAQ:ARDX

$3.08 -0.12 (-3.75%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$3.11 +0.03 (+0.94%)

As of 10/23/2026 07:59 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

HUTCHMED NASDAQ:HCM

$14.36 +0.08 (+0.56%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$14.38 +0.02 (+0.10%)

As of 10/23/2026 04:10 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Liquidia NASDAQ:LQDA

$42.65 +2.96 (+7.46%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$42.19 -0.46 (-1.08%)

As of 10/23/2026 07:59 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)

As of 10/23/2026

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARDX, LQDA, MOR, and HCM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARDX, LQDA, MOR, and HCM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARDX, LQDA, MOR, and HCM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ARDX, LQDA, MOR, and HCM Company Descriptions

Ardelyx NASDAQ:ARDX

HUTCHMED NASDAQ:HCM

Liquidia NASDAQ:LQDA

MorphoSys NASDAQ:MOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARDX, LQDA, MOR, and HCM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARDX, LQDA, MOR, and HCM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARDX, LQDA, MOR, and HCM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ARDX, LQDA, MOR, and HCM Company Descriptions

Ardelyx NASDAQ:ARDX

HUTCHMED NASDAQ:HCM

Liquidia NASDAQ:LQDA

MorphoSys NASDAQ:MOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools